Published: 2018-05-25

Assessment of health related quality of life (HRQol) in patients with Meige’s syndrome

Alok Verma, Pavan Singh, Saurabh Agarwal, Babita Gupta


Background: There is paucity of literature regarding health related quality of life (HRQoL) in Meige’s syndrome (MS) especially from India. This study assessed HRQoL in its global and disease specific aspect by previously validated instruments in patients with Meige’s syndrome.

Methods: The study was performed in AIIMS, New Delhi. Subjects with Meige’s syndrome as well as age and gender matched healthy controls were enrolled from Movement Disorder and botulinum toxin clinic, Department of Neurology, AIIMS, New Delhi. Uneducated patient, those could not read questionnaires and cases who had received botulinum toxin within 6 months were excluded from the study.

Results: A 14 pts of Meige’s syndrome were enrolled and 14 age matched controls were taken. All the pts of Meige’s syndrome scored worse in SF-36 as compared to controls in areas of role physical (p =0.002), bodily pain (p = 0.001), general health (p = <0.001), social functioning (p = 0.05) and role emotion (p = <0.001). 50% of patients with Meige’s syndrome had depression out of whom 21.4 % had moderate depression. Patients with Meige’s syndrome had significantly impaired scores in 10 of the 12 subscales which was profound in areas of ocular pain, near activities, distance activities, social functioning, role difficulties, dependency, driving, compared to borderline impairment in general vision, mental health, color vision.

Conclusions: This study clearly demonstrated that pts with Meige’s syndrome, suffered from significant impairment in HRQoL as compared to controls. Higher proportion of patients with Meige’s syndrome suffered from moderate depression compared to their control. Pts with Meige’s syndrome had severe impairment of vision related quality of life. 



Full Text:



Jankovic J, Tolosa E, editors. Parkinson's disease and movement disorders. Lippincott Williams & Wilkins; 2007. 5th Edi. 2007:321-347.

Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Movement disorders. 1988 Jan 1;3(3):188-94.

Khanh DL, Beate N. The prevalence of primary dystonia in general community. Neurology. 2003;61:1294-96.

The ESDE Colaborative group. A prevalence study of primary dystonia in eight European countries. J Neurol. 2000;247:77-792.

Das SK, Tapas KB. Community survey of primary dystonia in the city of Kolkata, India. Movement Disorders. 2007;14:2031-6.

Revicki DA, Osoba D, Fairclough D. Recommendation on health related quality of life research to support labeling and promotional claims in United States. Quality Life Res. 2000;9:887-900.

Ware JE, Kosinski M, Gandek. The factor structure of the SF-36 health survey in 10 countries: result from the IQOLA Project. International Study of Life Assessment. J Clin Epidemiol. 1998;51:1159-65.

Ware JE, Sherbourne CD. The 36 item short form (SF 36): Conceptual framework and item selection. Medcare. l992;30:473-83.

Mangione CM, Lee PP, Gutierrez PR. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-8.

Fahn S. Rating scales for blepharospasm. Adv Ophthal Plastic Reconstruct Surg. 1985;4:97-101.

Costa J, Espírito‐Santo CC, Borges AA, Ferreira J, Coelho MM, Moore P, Sampaio C. Botulinum toxin type A therapy for blepharospasm. The Cochrane Library. 2004 Jan 1.

Tucha 0, Naumann M, Berg D, Alders GL, Lange KW. Quality of life in patients with blepharospasm. Acta Neurol Scand. 2001;103:49-52.

Lindeboom R, De HR, Aramideh M, Speelman JD. The Blepharospasm Disability Scale: an instrument for the assessment of functional health in blepharospasm. Mov Disord. 1995;10:444-9.

Muller J, Kemmler G, Wissel J. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol. 2002;249:842-6.

Reimer J, Gilg K, Karow A, Esser J, Franke GH. Health related quality of life in blepharospasm or hemifacial spasm, Acta Neurol Scand. 2005:111;64-70.

Scheidt CE, Schuller B, Rayki O, Kommerell G, Deuschl G. Relative absence of psychopathology in benign essential blepharospasm and hemifacial spasm. Neurology. I996;47:43-5.

Grandas F, Elston JS. The significance of ophthalmologic symptom in idiopathic blepharospasm. Eye. 1998:2:767-77.

Tyler AH, Gerald M. Health-Related Quality of Life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol. 2006;124:116-9.